Alzheimer’s Therapeutics Market

Alzheimer’s Therapeutics Market Size, Market Forecast and Outlook By FMI

The Alzheimer’s therapeutics market was valued at USD 3.9 billion in 2025. The market is set to reach USD 4.3 billion by 2026-end and expand at a CAGR of 9.2% between 2026 and 2036 to reach USD 10.4 billion by 2036. Donepezil is expected to lead with a 67.7% drug class share, and hospital pharmacies will lead the distribution channel segment with a 35.0% share.

Key Takeaways, Market Size and Forecast

Metric	Value
Market Size (2025)	USD 3.9 Billion
Market Size (2036)	USD 10.4 Billion
CAGR (2026–2036)	9.2%
Incremental Opportunity (2026–2036)	USD 6.1 Billion
Leading Drug Class (2026)	Donepezil
Donepezil Share (2026)	67.7%
Leading Distribution Channel (2026)	Hospital Pharmacies
Hospital Pharmacies Share (2026)	35.0%
Fastest-Growing Country	Japan
Japan CAGR	12.0%

Summary of the Alzheimer’s Therapeutics Market

• Demand and Growth Drivers
  • Disease-modifying therapy approvals raise treatment value as amyloid-confirmed patients move into specialist drug pathways.
  • Oral symptom therapies keep baseline demand high as diagnosed patients continue daily treatment across care settings.
  • Hospital-based access expands as infused and injectable biologics need monitoring and pharmacy control.
• Product and Segment View
  • Donepezil is expected to lead the drug class segment with 67.7% share in 2026, reflecting broad first-line oral use.
  • Hospital pharmacies are poised to dominate distribution channel demand with 35.0% share in 2026, due to biologic handling needs.
  • Oral therapies are expected to hold high-volume administration mode demand as tablets fit long-term symptom management.
• Geography and Competitive Outlook
  • Japan is expected to record a CAGR of 12.0% through 2036, reflecting early biologic access and high dementia care need.
  • India is projected to expand at 11.6% CAGR by 2036, as branded generics serve a large diagnosis base.
  • Companies combining anti-amyloid therapy depth with payer access skill are strengthening their market position during the forecast period.
• Analyst Opinion
  • Nandini Roy, Principal Consultant for the Healthcare domain at FMI, says Alzheimer’s therapy has moved beyond symptom control into evidence-led care. Hospitals need clear patient selection rules with manageable safety workflows. Oral drugs support prescription volume while biologics shape early disease value. MRI capacity and reimbursement rules guide country launch planning.”
• Alzheimer’s Therapeutics Market Value Analysis
  • The alzheimer’s therapeutics market is moving from low-cost symptom management into a higher-value biologic access base.
  • Adoption is driven by anti-amyloid therapy approvals for early symptomatic patients with confirmed amyloid pathology.
  • The market benefits from deeper use of alzheimer’s diagnostics and therapeutics planning across memory clinics.
  • Demand is aided by diagnosis and monitoring systems needed before high-cost therapy use.
  • Care pathway cost creates a restraint as biologics need imaging checks and trained clinical teams.

Access to Alzheimer’s biologics now relies on treatment delivery, not approval alone. Kisunla is used for patients with mild cognitive impairment or mild dementia stage disease, and FDA states it is given as an IV infusion every four weeks. This limits use to centers able to confirm the right patient group and manage repeat infusion visits. Leqembi IQLIK adds a practical maintenance option, with Eisai stating the autoinjector contains 360 mg/1.8 mL and takes about 15 seconds to administer. This can reduce pressure on infusion centers after initial IV treatment. Reimbursement is another barrier. NICE stated donanemab slowed cognitive decline by four to seven months, but its cost-effectiveness estimate was five to six times above the usual NHS threshold. Companies need clinical evidence and payer value proof to improve real treatment access.

Alzheimer’s Therapeutics Market Definition

The Alzheimer’s therapeutics market includes prescription therapies used to manage symptoms or slow early disease progression. These products cover cholinesterase inhibitors, NMDA receptor antagonists, amyloid immunotherapies, and combination therapies across the broader CNS treatment and therapy field. Scope includes oral, intravenous, subcutaneous, and transdermal prescription formats. Diagnostics, care services, supplements, and research-only molecules are outside the scope.

Alzheimer’s Therapeutics Market Inclusions

Market scope covers all commercially traded Alzheimer’s therapeutics categorized by drug class including cholinesterase inhibitors and amyloid immunotherapies; distribution channel including hospital pharmacies and retail pharmacies; administration mode including oral therapies and intravenous therapies; patient stage, including mild cognitive impairment and mild dementia; and end users including hospitals and memory clinics. Revenue scope covers the 2026 to 2036 forecast period across prescription sales and institutional treatment channels, with adjacent care planning related to dementia management and future therapy pathways connected to gene therapy in cns disorder. Key stakeholders include Alzheimer’s drug manufacturers; biotechnology firms; hospital pharmacy networks; neurology clinics; memory care centers; retail pharmacy chains; clinical research organizations; diagnostic partners; payers; distributors; and regulatory bodies.

Alzheimer’s Therapeutics Market Exclusions

Scope does not include diagnostic imaging, cognitive tests, caregiver services, nutraceuticals, wellness products, or investigational molecules without commercial therapeutic sales.

Alzheimer’s Therapeutics Market Research Methodology

• Primary Research: FMI analysts reviewed neurology prescribing patterns, hospital pharmacy practices, payer access criteria, and manufacturer launch planning in important markets.
• Desk Research: Combined data from regulatory labels, company portfolios, payer coverage documents, and clinical guidance for Alzheimer’s drug use.
• Market sizing and forecasting: Added therapy use across drug classes, treatment stages, channels, and country access patterns from the bottom up.
• Data validation: Cross-checked every three months against approval status, reimbursement evidence, prescription behavior, and company product coverage.

Why is the Alzheimer’s Therapeutics Market Growing?

• Drug approvals for anti-amyloid therapies raise a higher-value treatment layer in early symptomatic alzheimer’s disease.
• Daily oral therapy use keeps prescription volume steady across patients outside biologic eligibility.
• Hospitals gain a larger role as infusion safety and MRI review become central to therapy access.

Global dementia burden is creating pressure for therapies able to slow clinical decline and reduce care intensity. WHO reported in March 2025 with 57 million people having dementia in 2021, and Alzheimer disease contributing 60% to 70% of cases. This large patient pool increases the need for drugs used earlier in the disease pathway. Therapy manufacturers gain value as health systems connect diagnosis and treatment review.

Access rules are reshaping the commercial pathway for anti-amyloid drugs. CMS reported in July 2024 with Medicare coverage available for Kisunla after traditional FDA approval, joining Leqembi under the national registry process. This coverage structure gives manufacturers a defined pathway, but it adds documentation pressure for hospitals. Sites able to manage registry entry and monitoring can convert eligible patients into treated volume.

Market Segmentation Analysis

• Donepezil is forecast to capture 67.7% of the drug class segment in 2026, helped by familiar oral prescribing across diagnosed alzheimer’s dementia.
• Hospital pharmacies are projected to hold 35.0% distribution channel share as biologic handling needs controlled storage and supervised dosing.
• Oral therapies are expected to represent 70.0% of administration mode use during 2026, supported by low-cost daily treatment across routine care settings.
• Mild dementia is forecast to contribute 46.0% of the patient stage segment, reflecting the early symptomatic focus of disease-modifying therapies.
• Hospitals are predicted to contribute 40.0% of end user value for the same year as infusion capacity and imaging-based monitoring shape biologic access.

The market for Alzheimer’s therapeutics is divided into groups based on drug class, distribution channel, administration mode, patient stage, end user, and region. There are cholinesterase inhibitors, NMDA receptor antagonists, amyloid immunotherapies, combination therapies, and other drug classes under drug class. By distribution channel, the market includes hospital pharmacies, retail pharmacies, drug stores, and online pharmacies. By administration mode, the market covers oral therapies, intravenous therapies, subcutaneous therapies, and transdermal therapies, with adjacent patient-care tools linked to digital therapeutics. Based on patient stage, it includes mild cognitive impairment, mild dementia, moderate dementia, and severe dementia. By end user, the market includes hospitals, memory clinics, retail care settings, home care settings, and research centers, while non-prescription products such as citicoline supplement are outside the core prescription therapy scope.

Insights into Alzheimer’s Therapeutics Market by Drug Class

• Donepezil is predicted to contribute 67.7% of drug class demand in 2026. Its long prescribing history and daily oral use keep it central across diagnosed alzheimer’s dementia patients.
• Memantine and amyloid immunotherapies address different treatment needs within the care pathway. Their value improves in moderate symptom control and early-stage biologic treatment planning.

Insights into Alzheimer’s Therapeutics Market by Distribution Channel

• Hospital pharmacies are projected to account for 35.0% of distribution channel share in 2026. Infused biologics require controlled handling and supervised administration across specialist treatment settings.
• Retail pharmacies raise routine oral prescription access across long-term symptom management. Hospital channels carry higher value as biologic therapy needs monitoring and pharmacy oversight.

Insights into Alzheimer’s Therapeutics Market by Administration Mode

• Oral therapies are expected to represent 70.0% of administration mode share in 2026. Tablets suit daily symptom care across home treatment and retail pharmacy channels.
• Intravenous and subcutaneous formats serve a narrower early-stage treatment base. Their value improves as anti-amyloid therapies move through specialist prescribing pathways.

Insights into Alzheimer’s Therapeutics Market by Patient Stage

• Mild dementia is forecast to account for 46.0% of patient stage share in 2026. Early symptomatic patients carry higher value as biologic labels focus on amyloid-confirmed treatment eligibility.
• Moderate and severe dementia patients continue using symptom-focused therapies across routine care. Disease-modifying biologics are mainly positioned before advanced functional decline develops.

Insights into Alzheimer’s Therapeutics Market by End User

• Hospitals are projected to hold 40.0% of end user share in 2026. Specialist neurology review and infusion capacity keep hospitals central to monitored Alzheimer’s biologic treatment.
• Memory clinics improve patient selection before therapy starts across early-stage Alzheimer’s care. Retail care and home care handle longer-term oral treatment after diagnosis and prescription review.

Alzheimer’s Therapeutics Market Drivers, Restraints and Opportunities

• Driver: Anti-amyloid approvals keep specialist Alzheimer’s therapy demand active as early-stage patients need disease-modifying options after amyloid confirmation.
• Restraint: High biologic price and full care-pathway cost can restrict access across public payer systems and smaller treatment centers.
• Opportunity: Subcutaneous maintenance dosing and biomarker triage create supplier differentiation for hospitals seeking lower service burden.

Alzheimer’s therapeutics demand is supported by earlier treatment decisions and better patient selection. Alzheimer’s Association reported in April 2026, lecanemab’s current treatment price was USD 26,500 per person per year. The same source cited an independent value-based range of USD 8,900 to USD 21,500. This price gap makes payer access stricter for anti-amyloid drugs. Manufacturers need evidence packages showing clinical value and practical stopping rules before broader reimbursement improves.

Biologic Price and Access Analysis

Biologic therapy is creating a higher-cost treatment layer inside Alzheimer’s care. Alzheimer’s Association reported in April 2026, Original Medicare patients generally face 20.0% coinsurance after the Part B deductible for covered physician-administered drugs. This out-of-pocket exposure affects patient affordability and site-of-care planning. Hospitals and manufacturers need reimbursement guidance before therapy starts. Stronger coverage support can reduce treatment delays for eligible patients.

Treatment Pathway Cost Analysis

Alzheimer’s therapeutics pricing is now evaluated based on total treatment cost with less focus on drug price alone. A Frontiers review reported in April 2026, current anti-amyloid pricing stood above USD 26,000 annually for lecanemab and USD 32,000 for donanemab. The same review placed total annual per-patient cost near USD 80,000 to USD 90,000 after imaging and monitoring with MRI. It included infusion administration within the full treatment cost estimate. This cost profile pushes manufacturers toward easier delivery formats and clearer patient-selection pathways.

Analysis of Alzheimer’s Therapeutics Market By Key Countries

Country	CAGR
Japan	12.0%
India	11.6%
Germany	11.0%
China	10.4%
UK	9.7%
USA	9.0%
France	8.6%

Source: Future Market Insights.

Alzheimer’s Therapeutics Market CAGR Analysis By Country

• Japan is projected to record 12.0% CAGR through 2036, aided by early biologic approval and stronger specialist treatment readiness.
• India is expected to expand at 11.6% CAGR as branded generic use grows across urban neurology centers.
• Germany’s 11.0% CAGR reflects specialist care networks and controlled biologic access after European approval.
• China is forecast to advance at 10.4% over the assessment period, supported by national dementia planning and broader diagnosis services.
• Mature reimbursement systems keep forecast growth measured in the UK at 9.7%, the USA at 9.0%, and France at 8.6%.

Demand for Alzheimer’s therapeutics is forecast to rise at 9.2% CAGR from 2026 to 2036. Country-level analysis covers major markets contributing to this forecast, with key markets listed below.

Demand Outlook for Alzheimer’s Therapeutics Market in Japan

Japan’s Alzheimer’s therapeutics industry is projected to record a CAGR of 12.0% through 2036. Real-world lecanemab adoption research published in 2025 reported about 6,000 treated patients in Japan during the first year after launch. This early use base aids demand for Japan Alzheimer’s therapeutics as hospitals build biologic workflows. Local suppliers gain from specialist centers needing therapy education and safety monitoring.

• Tokyo and Osaka memory centers create concentrated access points for biologic therapy review and patient monitoring.
• MHLW approval pathways have placed lecanemab and donanemab inside formal early Alzheimer’s treatment options.
• Japan’s aging care system favors therapies with measurable function benefit during early symptomatic disease.

Sales Analysis of Alzheimer’s Therapeutics Market in India

The Alzheimer’s therapeutics sector in India is expected to expand at a CAGR of 11.6% during the assessment period. India has a large, underdiagnosed dementia base and growing use of branded generics in neurology care. Metro hospitals create the first commercial base for premium therapy review. Drug makers benefit from broad oral therapy use before biologic access expands.

• Delhi NCR and Mumbai hospitals concentrate specialist dementia evaluation and branded therapy prescribing.
• Bengaluru and Hyderabad clinical networks make a practical base for neurology clinical trials and biomarker studies.
• Ayushman Bharat improves hospital access, but premium biologic funding will need separate payer pathways.

Demand Outlook for Alzheimer’s Therapeutics Market in the United States

The USA Alzheimer’s therapeutics industry is forecast to grow at a CAGR of 9.0% by 2036. Alzheimer’s Association reported in April 2025 with 7.2 million Americans aged 65 and older living with Alzheimer’s dementia. This patient base creates a large therapy pool, although biologic eligibility stays narrower. Medicare registry coverage and MRI monitoring decide how quickly approved products reach treated patients.

• CMS national registry rules shape Medicare access for Leqembi and Kisunla in approved early disease use.
• Boston and San Francisco academic centers influence specialist practice for anti-amyloid therapy monitoring.
• FDA labeling guides infusion site selection and safety review for amyloid-related imaging findings.

Opportunity Analysis of Alzheimer’s Therapeutics Market in Germany

The Alzheimer’s therapeutics segment in Germany is poised to advance at 11.0% CAGR over the forecast years. Germany has an established specialist care base and structured reimbursement review for branded medicines. A 2025 Robert Koch Institute study reported dementia prevalence of 2.8% among people aged 40 and older in 2022. This burden aids demand for Germany Alzheimer’s therapeutics, especially inside neurology-led care pathways.

• Berlin and Munich university hospitals provide specialist capacity for early Alzheimer’s therapy evaluation.
• AMNOG assessment affects commercial access for branded biologics after regulatory approval.
• Germany’s National Dementia Strategy increases local care networks and information services for diagnosed patients.

Future Outlook for Alzheimer’s Therapeutics Market in the United Kingdom

The UK Alzheimer’s therapeutics industry is expected to post 9.7% CAGR through 2036. MHRA licensed lecanemab for early Alzheimer’s disease in August 2024, and NICE reimbursement review kept NHS access controlled. NICE later estimated around 70,000 adults in England could have been eligible for lecanemab and donanemab treatment. Service providers with diagnostic planning and monitoring capacity can aid private access and future NHS readiness.

• NHS England service planning affects how quickly specialist centers can manage anti-amyloid therapy.
• London memory services provide concentrated capacity for amyloid confirmation and neurology review.
• MHRA product authorization makes a regulatory path as NICE value review limits public access.

Sales Analysis of Alzheimer’s Therapeutics Market in China

China Alzheimer’s therapeutics demand is expected to expand at 10.4% CAGR through 2036. The State Council reported in January 2025 with Alzheimer’s disease and other dementias surpassing 16 million people in China in 2021. This burden gives China a large addressable base for oral drugs and biologic therapy. Diagnosis access and payer acceptance will shape commercial conversion.

• Beijing and Shanghai tertiary hospitals provide early launch channels for amyloid therapies and biomarker services.
• China’s dementia action plan targets a prevention and control system by 2030.
• Dedicated dementia care units are targeted to exceed 50% of elderly care institutions by 2030.

In-depth Analysis of Alzheimer’s Therapeutics Market in France

France Alzheimer’s therapeutics demand is projected to rise at 8.6% CAGR through 2036. France has strong public payer discipline and formal health technology review for high-cost medicines. HAS refused early access for lecanemab in September 2025 before full review. This slows premium biologic access but preserves steady demand for oral therapies through retail channels.

• Paris university hospitals provide clinical capacity for early Alzheimer’s evaluation and specialist drug review.
• HAS assessment will influence timing for lecanemab reimbursement and wider biologic access.
• France’s memory consultation network enhances diagnosis capacity for patients needing therapy selection.

Competitive Landscape and Strategic Positioning

Alzheimer’s Therapeutics Market Analysis By Company

Competition in alzheimer’s therapeutics is split between branded biologic leaders and generic suppliers serving daily symptom treatment. Branded companies focus on clinical evidence and specialist delivery planning across neurology treatment centers. Generic manufacturers emphasize on oral therapy availability and pharmacy access for price-sensitive prescription volume.

• Eisai Co. Ltd. leads through Leqembi commercialization and deep anti-amyloid treatment experience across specialist neurology channels.
• Biogen and Eli Lilly compete on biologic development strength and access planning for specialist treatment centers.
• Generic manufacturers compete over oral symptom therapies and broad pharmacy reach for price-sensitive prescription volume.

Eisai has a strong position through Leqembi and its delivery development program. Biogen adds commercialization reach and clinical education depth across anti-amyloid therapy. Eli Lilly leverages Kisunla and finite-dosing use after amyloid plaque reduction. Novartis and Roche add pipeline relevance across disease biology and diagnostic connections. Aurobindo Pharma and Dr. Reddy’s Laboratories focus on oral therapy supply across retail channels. Viatris adds another generic position through broad pharmacy distribution and established prescription access.

Payer evidence needs and monitoring burden create the main barriers in biologic Alzheimer’s treatment. Stronger competitors are building patient selection tools and practical dosing workflows across specialist centers. Hospitals prefer manufacturers offering safety education and reimbursement help without adding workflow strain. Manufacturers combining solid clinical proof with simpler treatment delivery can earn stronger confidence from neurology teams and payers.

Key Companies in the Alzheimer’s Therapeutics Market

Key global companies leading the Alzheimer’s therapeutics market include:

• Eisai Co. Ltd., Biogen, and Eli Lilly have strong anti-amyloid therapy portfolios and global launch experience.
• Novartis, Roche, and AbbVie serve neurology demand through research depth and CNS portfolio reach.
• Aurobindo Pharma, Dr. Reddy’s Laboratories, and Viatris hold positions across oral generic therapies and retail channels.

Competitive Benchmarking: Alzheimer’s Therapeutics Market

Company	Anti-Amyloid Therapy Depth	Monitoring Workflow Strength	Channel Reach	Geographic Footprints
Eisai Co. Ltd.	High	High	Strong	Japan, Americas, China, EMEA, Asia, and Latin America
Biogen	High	High	Strong	USA, Switzerland, Europe, Brazil, China, Japan, and other international markets
Eli Lilly	High	High	Strong	USA, Europe, China, India, Japan, Latin America, and other global markets
Roche	Medium	High	Strong	Switzerland, USA, Europe, Asia Pacific, Latin America, and other worldwide locations
Novartis	Medium	Medium	Strong	Switzerland, Europe, USA, Asia, and other global locations
AbbVie	Medium	Medium	Moderate	North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
Aurobindo Pharma	Low	Low	Strong	India, USA, Europe, and over 150 global markets
Dr. Reddy’s Laboratories	Low	Low	Strong	India, USA, Europe, Russia and CIS countries, and other global markets
Viatris	Low	Low	Strong	USA, Europe, Asia Pacific, India, and over 165 markets and territories

Source: Future Market Insights.

Key Developments in Alzheimer’s Therapeutics Market

• In July 2025, Roche announced new Alzheimer’s portfolio data at AAIC 2025, including Phase Ib/IIa Brainshuttle AD results for trontinemab and the planned Phase III TRONTIER 1 and 2 studies in early symptomatic Alzheimer’s disease. The company announced plans for an additional Phase III trial in preclinical Alzheimer’s disease.
• In July 2025, Eli Lilly announced that the U.S. FDA approved a label update for Kisunla (donanemab-azbt), adding a new recommended titration dosing schedule for adults with early symptomatic Alzheimer’s disease. The company stated that the modified titration schedule lowered ARIA-E incidence versus the original schedule while maintaining comparable amyloid plaque removal and P-tau217 reduction.

Key Players in the Alzheimer’s Therapeutics Market

Major Global Players:

• Eisai Co. Ltd.
• Biogen
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.

Report Scope and Coverage

Alzheimer’s Therapeutics Market Breakdown By Drug Class, Distribution Channel, Administration Mode, Patient Stage, End User, And Region

Parameter	Details
Quantitative Units	USD 4.3 billion to USD 10.4 billion, at a CAGR of 9.2%
Market Definition	Alzheimer’s therapeutics include prescription therapies used to manage symptoms or slow disease progression in diagnosed patients.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	USA, UK, Germany, France, China, India, Japan, and 30 plus countries
Key Companies Profiled	Eisai Co. Ltd., Biogen, Eli Lilly, Roche, Novartis, AbbVie, Aurobindo Pharma, Dr. Reddy’s Laboratories, Viatris
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology starting with therapy demand and verified access patterns.

Alzheimer’s Therapeutics Market by Segments

Alzheimer’s Therapeutics Market Segmented by Drug Class:

• Cholinesterase Inhibitors
• NMDA Receptor Antagonists
• Amyloid Immunotherapies
• Combination Therapies
• Other Drug Classes

Alzheimer’s Therapeutics Market Segmented by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Alzheimer’s Therapeutics Market Segmented by Administration Mode:

• Oral Therapies
• Intravenous Therapies
• Subcutaneous Therapies
• Transdermal Therapies

Alzheimer’s Therapeutics Market Segmented by Patient Stage:

• Mild Dementia
• Mild Impairment
• Moderate Dementia
• Severe Dementia

Alzheimer’s Therapeutics Market Segmented by End User:

• Hospitals
• Memory Clinics
• Retail Care
• Home Care
• Research Centers

Alzheimer’s Therapeutics Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Rest of Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East and Africa
  • Saudi Arabia
  • Other GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Research Sources and Bibliography

1. World Health Organization. (2025, March 31). Dementia. World Health Organization.
2. Centers for Medicare & Medicaid Services. (2024, July 11). New Alzheimer’s drugs: Updates to CMS National Patient Registry. CMS.
3. USA Food and Drug Administration. (2024, July 2). FDA approves treatment for adults with Alzheimer’s disease. FDA.
4. Eisai Co., Ltd. (2025, August 29). FDA approves LEQEMBI® IQLIK (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer’s disease. Eisai.
5. Eli Lilly and Company. (2025, July 9). FDA approves updated label for Lilly’s Kisunla® (donanemab-azbt) with new dosing in early symptomatic Alzheimer’s disease. Eli Lilly and Company.
6. National Institute for Health and Care Excellence. (2024, October 23). New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS, says NICE. NICE.
7. Alzheimer’s Association. (2025, April 29). 2025 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia.
8. State Council of the People’s Republic of China. (2025, January 4). China launches action plan to tackle dementia amid aging population. The State Council of the People’s Republic of China.
9. Robert Koch Institute. (2025). Dementia: Prevalence, trends and regional patterns in Germany. Journal of Health Monitoring, 10(1).
10. Alzheimer’s Association. (2026). 2026 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia, 22. Alzheimer's Association 2026 Alzheimer's Disease Facts and Figures
11. Ouro, A., Ben-Dor, G. A., Debasa-Mouce, M., Gulkarov, S., De Leon, J., Castro-Mosquera, M., Sobrino, T., Bougea, A., & Reiss, A. B. (2026). Monoclonal antibodies and small molecules: On the cutting edge of Alzheimer’s disease therapy. Frontiers in Cell and Developmental Biology, 14, 1766762. doi: 10.3389/fcell.2026.1766762 Frontiers | Monoclonal antibodies and small molecules: on the cutting edge of Alzheimer’s disease therapy
12. F. Hoffmann-La Roche Ltd. (2025, July 28). Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC. Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC
13. Eli Lilly and Company. (2025, July 9). FDA approves updated label for Lilly’s Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer’s disease. FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease | Eli Lilly and Company

This Report Answers

• What is the current and future size of the Alzheimer’s therapeutics market?
• How fast is the Alzheimer’s therapeutics market expected to expand between 2026 and 2036?
• Which drug class is expected to lead the market by 2026?
• Which distribution channel is expected to account for the leading demand by 2026?
• What factors are driving demand for Alzheimer’s therapeutics globally?
• How are anti-amyloid approvals influencing therapy access?
• Why do hospital pharmacies hold a major role in Alzheimer’s biologic delivery?
• How are diagnostics and biomarkers affecting patient selection?
• Which countries are projected to record faster expansion through 2036?
• What is driving market expansion in Japan and India?
• Who are the key companies active in the Alzheimer’s therapeutics market?
• How does FMI estimate and validate the market forecast?